X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HBI0101 (NXC-201) is a BCMA-targeted investigational CAR-T cell therapy. It is being evaluated in phase 1/2 clinical trials for the treatment of multiple myeloma.
Lead Product(s): NXC-201
Therapeutic Area: Oncology Product Name: HBI0101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2024
Details:
The company intends to use the net proceeds for company’s lead cell therapy asset, NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, currently being evaluated in an ongoing Phase 1/2 trial.
Lead Product(s): NXC-201
Therapeutic Area: Genetic Disease Product Name: NXC-201
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Titan Partners Group LLC
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 08, 2024
Details:
HBI0101 (NXC-201) is a BCMA-targeted investigational CAR-T cell therapy. It is being evaluated in phase 1/2 clinical trials for the treatment of relapsed/refractory AL Amyloidosis.
Lead Product(s): NXC-201
Therapeutic Area: Genetic Disease Product Name: HBI0101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2024
Details:
The Company intends to use the net proceeds for company’s lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, currently being evaluated in an ongoing Phase 1/2 trial.
Lead Product(s): NXC-201
Therapeutic Area: Genetic Disease Product Name: NXC-201
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Titan Partners Group LLC
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 05, 2024
Details:
NXC-201, a next generation CAR-T cell therapy, is currently being evaluated in a Phase 1b/2a clinical trial for the treatment of Multiple Myeloma and received orphan drug designation from FDA.
Lead Product(s): NXC-201
Therapeutic Area: Oncology Product Name: NXC-201
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Nexcella
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details:
IMX-110 demonstrated 100% tumor shrinkage in advanced metastatic colorectal cancer at the lowest dose of IMX-110 Iin combination with tislelizumab (anti-PD-1 antibody).
Lead Product(s): IMX-110,Tislelizumab
Therapeutic Area: Oncology Product Name: IMX-110
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
The Company intends to use net proceeds for its IMX-110 plus tislelizumab Phase 1b combination clinical trial and its IMX-110 monotherapy clinical trial. IMX-110 is a potential first-line therapy for soft tissue sarcoma.
Lead Product(s): Doxorubicin Hydrochloride,Tislelizumab
Therapeutic Area: Oncology Product Name: IMX-110
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bridgewest Group
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 14, 2023
Details:
IMX-110 demonstrated 100% tumor shrinkage in advanced metastatic colorectal cancer at the lowest dose of IMX-110 Iin combination with tislelizumab (anti-PD-1 antibody).
Lead Product(s): IMX-110,Tislelizumab
Therapeutic Area: Oncology Product Name: IMX-110
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
IMX-110 monotherapy, developed using SMARxT tissue-specific platform , is a tissue-specific therapeutic that simultaneously attacks all 3 components of the tumor micro-environment. It is currently being evaluated for advanced solid tumors.
Lead Product(s): IMX-110,Tislelizumab
Therapeutic Area: Oncology Product Name: IMX-110
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
IMX-110 monotherapy, developed using SMARxT tissue-specific platform , is a tissue-specific therapeutic that simultaneously attacks all 3 components of the tumor micro-environment. It is currently being evaluated for advanced solid tumors.
Lead Product(s): IMX-110
Therapeutic Area: Oncology Product Name: IMX-110
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
